4.5 Article

Consensus for genes to be included on cancer panel tests offered by UK genetics services: guidelines of the UK Cancer Genetics Group

期刊

JOURNAL OF MEDICAL GENETICS
卷 55, 期 6, 页码 372-377

出版社

BMJ PUBLISHING GROUP
DOI: 10.1136/jmedgenet-2017-105188

关键词

-

资金

  1. UK Genetic Testing Network (UKGTN)
  2. MRC [G0700491] Funding Source: UKRI

向作者/读者索取更多资源

Genetic testing for hereditary cancer predisposition has evolved rapidly in recent years with the discovery of new genes, but there is much debate over the clinical utility of testing genes for which there are currently limited data regarding the degree of associated cancer risk. To address the discrepancies that have arisen in the provision of these tests across the UK, the UK Cancer Genetics Group facilitated a 1-day workshop with representation from the majority of National Health Service (NHS) clinical genetics services. Using a preworkshop survey followed by focused discussion of genes without prior majority agreement for inclusion, we achieved consensus for panels of cancer genes with sufficient evidence for clinical utility, to be adopted by all NHS genetics services. To support consistency in the delivery of these tests and advice given to families across the country, we also developed management proposals for individuals who are found to have pathogenic mutations in these genes. However, we fully acknowledge that the decision regarding what test is most appropriate for an individual family rests with the clinician, and will depend on factors including specific phenotypic features and the family structure.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

Article Genetics & Heredity

UK recommendations for SDHA germline genetic testing and surveillance in clinical practice

Helen Hanson, Miranda Durkie, Fiona Lalloo, Louise Izatt, Terri P. McVeigh, Jackie A. Cook, Carole Brewer, James Drummond, Samantha Butler, Treena Cranston, Ruth Casey, Tricia Tan, Daniel Morganstein, Diana M. Eccles, Marc Tischkowitz, Clare Turnbull, Emma Roisin Woodward, Eamonn R. Maher

Summary: SDHA PGV carriers are common in patients with paraganglioma and phaeochromocytoma, and the variant often presents as sporadic tumors in patients without family history. Studies show that the penetrance of SDHA-associated tumors is low, which poses challenges for surveillance and management.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

A digital pathway for genetic testing in UK NHS patients with cancer: BRCA-DIRECT randomised study internal pilot

Bethany Torr, Christopher Jones, Subin Choi, Sophie Allen, Grace Kavanaugh, Monica Hamill, Alice Garrett, Suzanne MacMahon, Lucy Loong, Alistair Reay, Lina Yuan, Mikel Valganon Petrizan, Kathryn Monson, Nicky Perry, Lesley Fallowfield, Valerie Jenkins, Rochelle Gold, Amy Taylor, Rhian Gabe, Jennifer Wiggins, Anneke Lucassen, Ranjit Manchanda, Ashu Gandhi, Angela George, Michael Hubank, Zoe Kemp, D. Gareth Evans, Stephen Bremner, Clare Turnbull

Summary: This study introduces a rapid digital pathway for genetic testing in breast cancer patients, which improves the uptake of testing with the support of clinicians and a genetics specialist hotline. The results demonstrate high satisfaction and similar outcomes for both the fully digital and partially digital pathways.

JOURNAL OF MEDICAL GENETICS (2022)

Article Oncology

Predominance of BRCA2 Mutation and Estrogen Receptor Positivity in Unselected Breast Cancer with BRCA1 or BRCA2 Mutation

Pascal Pujol, Kevin Yauy, Amandine Coffy, Nicolas Duforet-Frebourg, Sana Gabteni, Jean-Pierre Daures, Frederique Penault Llorca, Frederic Thomas, Kevin Hughes, Clare Turnbull, Virginie Galibert, Chloe Rideau, Carole Corsini, Laetitia Collet, Benoit You, David Genevieve, Nicolas Philippe

Summary: The meta-analysis revealed a higher prevalence of gBRCA2 in unselected breast cancer patients. Additionally, the majority of tumors in breast cancer patients with gBRCA are estrogen receptor-positive.

CANCERS (2022)

Article Oncology

Analysis of rare disruptive germline mutations in 2135 enriched BRCA-negative breast cancers excludes additional high-impact susceptibility genes

C. Loveday, A. Garrett, P. Law, S. Hanks, E. Poyastro-Pearson, J. W. Adlard, J. Barwell, J. Berg, A. F. Brady, C. Brewer, C. Chapman, J. Cook, R. Davidson, A. Donaldson, F. Douglas, L. Greenhalgh, A. Henderson, L. Izatt, A. Kumar, F. Lalloo, Z. Miedzybrodzka, P. J. Morrison, J. Paterson, M. Porteous, M. T. Rogers, L. Walker, D. Eccles, D. G. Evans, K. Snape, H. Hanson, R. S. Houlston, C. Turnbull

Summary: This study is the largest case-control whole-exome analysis of breast cancer to date. While there may be additional breast cancer susceptibility genes, genes of high penetrance are likely to have very low mutational frequency.

ANNALS OF ONCOLOGY (2022)

Article Oncology

Germline-focused analysis of tumour-detected variants in 49,264 cancer patients: ESMO Precision Medicine Working Group recommendations

Z. Kuzbari, C. Bandlamudi, C. Loveday, A. Garrett, M. Mehine, A. George, H. Hanson, K. Snape, A. Kulkarni, S. Allen, S. Jezdic, R. Ferrandino, C. B. Westphalen, E. Castro, J. Rodon, J. Mateo, G. J. Burghel, M. F. Berger, D. Mandelker, C. Turnbull

Summary: The ESMO PMWG updated their recommendations on follow-up of putative germline variants detected on tumour-only sequencing, based on an analysis of an expanded dataset including 49,264 paired tumour-normal samples. They applied filters to tumour-detected variants and found that a subset of these variants can produce actionable true germline variants. They have revised the guidelines and included new genes for germline follow-up.

ANNALS OF ONCOLOGY (2023)

Article Oncology

Incorporating Alternative Polygenic Risk Scores into the BOADICEA Breast Cancer Risk Prediction Model

Nasim Mavaddat, Lorenzo Ficorella, Tim Carver, Andrew Lee, Alex P. Cunningham, Michael Lush, Joe Dennis, Marc Tischkowitz, Kate Downes, Donglei Hu, Eric Hahnen, Rita K. Schmutzler, Tracy L. Stockley, Gregory S. Downs, Tong Zhang, Anna M. Chiarelli, Stig E. Bojesen, Cong Liu, Wendy K. Chung, Monica Pardo, Lidia Feliubadalo, Judith Balmana, Jacques Simard, Antonis C. Antoniou, Douglas F. Easton

Summary: BOADICEA model can identify women at higher or lower risk of developing breast cancer by incorporating PRS. Different variations of the PRS were evaluated, and logistic regression and retrospective likelihood approaches were used to estimate the parameters. The study showed that BOADICEA can be adapted to different PRS, providing a comprehensive breast cancer risk assessment.

CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION (2023)

Article Genetics & Heredity

UK consensus recommendations for clinical management of cancer risk for women with germline pathogenic variants in cancer predisposition genes: RAD51C, RAD51D, BRIP1 and PALB2

Helen Hanson, Anjana Kulkarni, Lucy Loong, Grace Kavanaugh, Bethany Torr, Sophie Allen, Munaza Ahmed, Antonis C. Antoniou, Ruth Cleaver, Tabib Dabir, D. Gareth Evans, Ellen Golightly, Rosalyn Jewell, Kelly Kohut, Ranjit Manchanda, Alex Murray, Jennie Murray, Kai-Ren Ong, Adam N. Rosenthal, Emma Roisin Woodward, Diana M. Eccles, Clare Turnbull, Marc Tischkowitz, Fiona Lalloo

Summary: This paper presents a summary of the process and key recommendations from a national consensus on the clinical management of BRIP1, PALB2, RAD51D, and RAD51C carriers.

JOURNAL OF MEDICAL GENETICS (2023)

Article Genetics & Heredity

Germline mismatch repair (MMR) gene analyses from English NHS regional molecular genomics laboratories 1996-2020: development of a national resource of patient-level genomics laboratory records

Lucy Loong, Catherine Huntley, Fiona McRonald, Francesco Santaniello, Joanna Pethick, Bethany Torr, Sophie Allen, Oliver Tulloch, Shilpi Goel, Brian Shand, Tameera Rahman, Margreet Luchtenborg, Alice Garrett, Richard Barber, Tin Bedenham, David Bourn, Kirsty Bradshaw, Claire Brooks, Jonathan Bruty, George J. Burghel, Samantha Butler, Chris Buxton, Alison Callaway, Jonathan Callaway, James Drummond, Miranda Durkie, Joanne Field, Lucy Jenkins, Terri P. McVeigh, Roger Mountford, Rodney Nyanhete, Evgenia Petrides, Rachel Robinson, Tracy Scott, Victoria Stinton, James Tellez, Andrew J. Wallace, Laura Yarram-Smith, Kate Sahan, Nina Hallowell, Diana M. Eccles, Paul Pharoah, Marc Tischkowitz, Antonis C. Antoniou, D. Gareth Evans, Fiona Lalloo, Gail Norbury, Eva Morris, John Burn, Steven Hardy, Clare Turnbull

Summary: This study describes the national patterns of NHS analysis of MMR genes in England using individual-level data submitted to NDRS by regional molecular genetics laboratories. The NDRS MMR dataset is a unique national amalgamation of clinical and genomic patient data, enabling data linkage to other national datasets. This resource can enable longitudinal research and form the basis of a live national genomic disease registry.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Endoscopic surveillance with systematic random biopsy for the early diagnosis of hereditary diffuse gastric cancer: a prospective 16-year longitudinal cohort study

Colin Y. C. Lee, Adriaan Olivier, Judith Honing, Anne-Marie Lydon, Susan Richardson, Maria O'Donovan, Marc Tischkowitz, Rebecca C. Fitzgerald, Massimiliano di Pietro

Summary: Hereditary diffuse gastric cancer, caused by CDH1 gene mutations, is characterized by early-onset signet ring cell carcinoma. Prophylactic total gastrectomy is the recommended treatment. This study assessed different sampling strategies for detecting signet ring cell carcinoma and identified criteria for characterizing endoscopic lesions in hereditary diffuse gastric cancer.

LANCET ONCOLOGY (2023)

Article Hematology

Germline predisposition to haematological malignancies: Best practice consensus guidelines from the UK Cancer Genetics Group (UKCGG), CanGene-CanVar and the NHS England Haematological Oncology Working Group

Beverley Speight, Helen Hanson, Clare Turnbull, Steven Hardy, James Drummond, Jamshid Khorashad, Christopher Wragg, Paula W. Page, Nicholas Parkin, Ana Rio-Machin, Jude Fitzgibbon, Austin Gladston Kulasekararaj, Angela Hamblin, Polly P. Talley, Terri McVeigh, Katie Snape

Summary: The implementation of whole genome sequencing and large somatic gene panels in haematological malignancies has led to the identification of individuals with potential germline predisposition to such diseases. However, there are currently no established guidelines for managing carriers of these variants or their at-risk relatives. To address this gap, a workshop was held to establish consensus guidelines on clinical and laboratory pathways for managing disease-causing germline variations. The workshop focused on specific genes and achieved high consensus on standardised reporting, variant classification, multidisciplinary team working, and patient support.

BRITISH JOURNAL OF HAEMATOLOGY (2023)

Article Genetics & Heredity

Position statement of the International Society for Gastrointestinal Hereditary Tumors (InSiGHT) on APC I1307K and cancer risk

Laura Valle, Lior H. H. Katz, Andrew Latchford, Pilar Mur, Victor Moreno, Ian M. Frayling, Brandie Heald, Gabriel Capella

Summary: Constitutional pathogenic variants in the APC gene cause familial adenomatous polyposis, while APC c.3920T>A; p.Ile1307Lys (I1307K) is associated with a moderate increased risk of colorectal cancer (CRC), specifically in individuals of Ashkenazi Jewish descent. Different guidelines exist regarding genetic testing and clinical management for I1307K, due to inconclusive results in non-Ashkenazi populations. The International Society for Gastrointestinal Hereditary Tumors (InSiGHT) has generated a position statement on the APC I1307K allele to provide recommendations and address knowledge gaps.

JOURNAL OF MEDICAL GENETICS (2023)

Article Oncology

Utility of polygenic risk scores in UK cancer screening: a modelling analysis

Catherine Huntley, Bethany Torr, Amit Sud, Charlie F. Rowlands, Rosalind Way, Katie Snape, Helen Hanson, Charles Swanton, John Broggio, Anneke Lucassen, Margaret McCartney, Richard S. Houlston, Aroon D. Hingorani, Michael E. Jones, Clare Turnbull

Summary: It is proposed that polygenic risk scores (PRSs), by targeting high-risk individuals, can improve the efficiency of cancer screening programs and expand their application to new age groups and types of cancer. This study presents an overview of the performance of PRS tools and the benefits and harms of PRS-stratified cancer screening for eight example cancers.

LANCET ONCOLOGY (2023)

Editorial Material Medicine, General & Internal

Realistic expectations are key to realising the benefits of polygenic scores

Amit Sud, Rachel H. Horton, Aroon D. Hingorani, Ioanna Tzoulaki, Clare Turnbull, Richard S. Houlston, Anneke Lucassen

BMJ-BRITISH MEDICAL JOURNAL (2023)

Meeting Abstract Oncology

BRCA-DIRECT: A randomised UK study evaluating a digital pathway for germline genetic testing and non-inferiority of digitally-delivered information in women with breast cancer

B. Torr, S. Choi, S. Allen, M. Hamill, G. Kavanaugh, S. MacMahon, E. Poyastro-Pearson, L. Yuan, M. Valganon-Petrizan, A. George, V. A. Jenkins, L. Fallowfield, R. Manchanda, A. Gandhi, G. Evans, Z. Kemp, M. Hubank, C. Turnbull

ANNALS OF ONCOLOGY (2023)

Article Oncology

The Contribution of Germline Pathogenic Variants in Breast Cancer Genes to Contralateral Breast Cancer Risk in BRCA1/BRCA2/PALB2-Negative Women

Alexey Larionov, Eleanor Fewings, James Redman, Mae Goldgraben, Graeme Clark, John Boice, Patrick Concannon, Jonine Bernstein, David V. Conti, Marc WECARE Study Collaborative Grp, Marc Tischkowitz

Summary: In this study, researchers used genetic sequencing technologies to investigate the hereditary causes of second breast cancer in individuals who do not have alterations in the main breast cancer genes (BRCA1, BRCA2 and PALB2). They found that younger women with second breast cancers had a higher number of inherited gene alterations compared to women with only one breast cancer. This study improves our understanding of the hereditary contribution to second breast cancers.

CANCERS (2023)

暂无数据